Deutsche Bank AG Invests $14.03 Million in CG Oncology, Inc. $CGON

Deutsche Bank AG acquired a new stake in CG Oncology, Inc. (NASDAQ:CGON - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 197,514 shares of the company's stock, valued at approximately $14,033,000. Deutsche Bank AG owned 0.22% of CG Oncology at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of CGON. NFSG Corp acquired a new stake in CG Oncology in the 1st quarter worth $34,000. Comerica Bank lifted its stake in shares of CG Oncology by 100.4% in the fourth quarter. Comerica Bank now owns 1,028 shares of the company's stock valued at $43,000 after buying an additional 515 shares during the period. LPL Financial LLC grew its position in CG Oncology by 9.8% during the fourth quarter. LPL Financial LLC now owns 6,201 shares of the company's stock worth $257,000 after buying an additional 551 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in CG Oncology by 33.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company's stock worth $163,000 after buying an additional 972 shares in the last quarter. Finally, Fifth Third Bancorp bought a new position in CG Oncology during the first quarter valued at about $74,000. Institutional investors and hedge funds own 26.56% of the company's stock.

CG Oncology Stock Performance

Shares of NASDAQ CGON opened at $79.81 on Friday. CG Oncology, Inc. has a 52-week low of $25.25 and a 52-week high of $80.97. The business has a fifty day moving average of $71.31 and a two-hundred day moving average of $65.54. The stock has a market cap of $7.07 billion, a PE ratio of -29.67 and a beta of 0.23.

CG Oncology (NASDAQ:CGON - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.24). CG Oncology had a negative return on equity of 25.20% and a negative net margin of 3,602.68%.The firm had revenue of $1.16 million during the quarter, compared to the consensus estimate of $0.36 million. Analysts predict that CG Oncology, Inc. will post -3.27 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $74.54, for a total value of $74,540.00. Following the completion of the transaction, the director owned 1,000 shares in the company, valued at approximately $74,540. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director James Mulay sold 24,165 shares of the business's stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $75.16, for a total value of $1,816,241.40. Following the completion of the transaction, the director directly owned 24,165 shares in the company, valued at $1,816,241.40. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 38,129 shares of company stock valued at $2,738,357. 4.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of CG Oncology in a report on Friday, July 17th. JPMorgan Chase & Co. boosted their price objective on CG Oncology from $91.00 to $96.00 and gave the company an "overweight" rating in a research report on Monday, May 11th. Wedbush boosted their price objective on CG Oncology from $77.00 to $80.00 and gave the company an "outperform" rating in a research report on Monday, May 11th. HC Wainwright restated a "buy" rating and issued a $100.00 target price on shares of CG Oncology in a research note on Wednesday, July 29th. Finally, Piper Sandler raised their target price on CG Oncology from $82.00 to $85.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $83.18.

About CG Oncology

CG Oncology, Inc NASDAQ: CGON is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source